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-carotene  (BC),  a  lipid-soluble  tetraterpene  precursor  to vitamin  A,  widely  distributed  in plants,  includ-
ing  many  used  in  human  diet,  has  well-known  health-enhancing  properties,  including  reducing  risk
of  and  treatment  for certain  diseases.  Nevertheless,  BC  may  also  act  to  promote  disease  through  the
activity  of  BC  derivatives  that form  in the  presence  of  external  toxicants  such  as  cigarette  smoke
and  endogenously-produced  reactive  oxygen  species.  The  present  investigation  evaluates  the  dose-
dependent  cardioprotective  and  possibly  harmful  properties  of BC  in  a rat  model.  Adult  male  rats were
gavage-fed  BC  for 4  weeks,  at  dosages  of  either  0,  30 or  150  mg/kg/day.  Then,  hearts  excised  from  the
animals  were  mounted  in a “working  heart”  apparatus  and  subjected  to 30 min  of  global  ischemia,  fol-
lowed  by  120  min  of  reperfusion.  A  panel  of  cardiac  functional  evaluations  was  conducted  on each  heart.
Infarct  size  and  total  antioxidant  capacity  of the  myocardium  were  assessed.  Heart  tissue content  of heme
oxygenase-1  (HO-1)  by  Western  blot  analysis;  and  potential  direct  cytotoxic  effects  of BC by  MTT  assay
were  evaluated.  Hearts  taken  from  rats  receiving  30  mg/kg/day  BC exhibited  signiﬁcantly  improved  heart
function  at lower  reperfusion  times,  but lost  this  protection  at higher  BC dosage  and  longer  reperfusion
times.  Myocardial  HO-1  content  was  signiﬁcantly  elevated  dose-responsively  to both  BC dosage.  Finally,
in vitro evaluation  of BC  on H9c2  cells  showed  that  the  agent  signiﬁcantly  improved  vitality  of  these  cells
in  a dose  range  of  2.5–10  M.Although  data  presented  here  do not  allow  for a comprehensive  mechanistic  explanation  for  reduced
cardioprotection  at high dose  BC,  it is speculated  that  since  Fe2+ produced  as a metabolite  of HO-1  activity,
may  determine  whether  BC  acts  as  an antioxidant  or prooxidant  agent,  the strong  induction  of this  enzyme
in  response  to ischemia/reperfusion-induced  oxidative  stress  may  account  for  the  high-dose  BC  loss  of
cardioprotection.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
.1. “Functional foods” in prevention of and management of
hronic illnessIncreasingly intensive efforts are currently being made to char-
cterize properties of plant materials forming regular components
f human diet and expand the range of their use in healthcare.
∗ Corresponding author at: University of Debrecen, Faculty of Pharmacy, Depart-
ent of Pharmacology, Bioanalytical Division, H-4032 Debrecen, Nagyerdei krt. 98,
ungary. Fax: +36 52 255 586.
E-mail address: bak.istvan@pharm.unideb.hu (I. Bak).
ttp://dx.doi.org/10.1016/j.phrs.2015.07.021
043-6618/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article 
/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Substantial ongoing increases in serious chronic diseases, partic-
ularly obesity- and lifestyle-related cardiovascular disorders and
related co-morbidities, provide compelling incentive for use of nat-
ural products in healthcare—particularly in the form of “functional
foods”, which are items in normal diet conﬁgured to prevent and/or
mitigate disease. Such substances are increasingly attractive to
healthcare providers, since they are reasonably priced compared to
prescription drugs and other potentially traumatic interventions.
Moreover, health-enhancing properties for many of these mate-
rials have evolved in tandem with vertebrates as mutual adaptive
strategies, a process called “xenohormesis” [1]. Hence, there is com-
pelling incentive to encourage adoption of diets rich in fruits, seeds,
vegetables, legumes, ﬁsh oil and other materials rich in compounds
that strengthen and stabilize healthy homeostatic processes and
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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educe risk of cancers, cardiovascular diseases and many other
hronic illnesses.
.2. ˇ-Carotene: chemical and biological properties
The present investigation explores the capacity of the vitamin
 precursor -carotene (BC) to inﬂuence aspects of myocardial
ell, tissue, and organ function that may  will allow development of
ovel strategies for use of this compound in prevention and man-
gement of heart disease. This tetraterpene carotenoid is a 536 Da
ipid-soluble plant pigment, widely distributed in nature, includ-
ng many plants regularly consumed by animals and humans [2].
t is intensely red–orange and is responsible for multi-hued col-
ration in many plant species; and is also used as a commercial
ood colorant. Many human foods contain the compound, notably
ams, pumpkins and carrots. Some of its medical beneﬁts are well
stablished. For example, the compound has been demonstrated
oderately effective as adjuvant treatment in erythropoietic pro-
oporphyria and has additionally shown some promise also been
sed to reducing risk of age-related macular degeneration; and sus-
eptibility to breast cancer risk in pre-menopausal women [3–5].
 signiﬁcant cautionary note on clinical use of BC, is evidence that
ung cancer risk is increased in smokers by high-dose consumption
f the agent [6]. This effect is hypothesized to occur due to insta-
ility of the compound in the presence of tobacco smoke—causing
ts degradation to carcinogenic metabolites [7].
.3. Ischemia-reperfusion injury to cardiovascular tissue and
ntioxidant defense
The present investigation, which evaluates cardiovascular
ffects of BC, is focused on processes underlying ischemia and
eperfusion (I/R) injury to the myocardium. Heart disease and
ardiac surgery frequently involve procedures that deprive heart
issue of oxygenated blood, resulting in ischemia, a disruption of
ormal tissue homeostasis. Further derangement of tissue function
ay  occur as a result of re-oxygenation by restoration of blood ﬂow
reperfusion), a process that triggers a burst expression in phys-
ologic production of highly reactive oxygen-containing species
uring the ﬁrst 5 min  of blood reﬂow [8]. These compounds greatly
ncrease oxidative stress on reperfused tissues and effects that typ-
cally include oxidation of myocardial membrane lipids resulting
n impairment of cell membrane function. This oxidative stress
ncrease is a primary cause of reperfusion-induced damage [9].
dverse effects on cardiovascular function caused by these pro-
esses may  be counteracted by antioxidant compounds capable of
cavenging oxygen-containing free radicals that are the primary
gents of oxidative stress-mediated damage. Such cytoprotective
gents of (mainly) plant origin produce carotenoids, notably BC,
long with polyphenolic compounds and other phytochemicals
uch as ﬂavonoids, anthocyanidins, proanthocyanidins and other
arotenoids which have well documented beneﬁts to cardiovascu-
ar health [10–14].
.4. ˇ-Carotene: a double-edged sword in health maintenance
The effects of BC have been intensively studied, and both ben-
ﬁcial and potentially harmful effects of the compound have been
oted [6,7]. In addition to its ability to affect risk and pathogen-
sis of cancer, BC has been considered for use in management
f heart disease based on its free radical scavenging capacities,
ith the cautionary note that it may  also act as a tissue-damaging
rooxidant—depending on the physiologic environment [15,16].
everal clinical studies can be found having investigated the cardio-
ascular effects of BC, but all these results are rather controversial.
ost of these studies found that BC had no any beneﬁt and mayesearch 100 (2015) 148–156 149
have had adverse effects on the risk of death from cardiovascu-
lar diseases mainly among smokers [17–19]. The cardioprotective
value of beta carotene also appears to vary among individuals based
on genetic factors. This effect is illustrated by an intriguing April
2015 report demonstrating that healthy Korean women  bearing
single nucleotide polymorphisms that correlate with arterial stiff-
ening, were differentially protected by dietary supplementation
with BC, along with folate and vitamin E [20]. A primary mechanism
by which BC counteracts pathogenesis of cardiovascular disease
has recently been shown to result from the compound’s ability
to abate atherogenic processes by inhibition of peroxidation of
cardiac-associated lipids [21].
The investigation described in the present report was  under-
taken to evaluate the effects of BC administration in a rat model,
segregated into groups administered two  different BC dosages dur-
ing a 4-week period. One test group, deﬁned as “low dose” (LD) was
fed 30 mg/kg/day; and a second, “high dose” (HD) group received
150 mg/kg/day, with a cohort of control (C) rats given hydrox-
yethyl cellulose-water vehicle. Following sacriﬁce at the end of
the 4-week dosing period, hearts surgically excised and mounted
in a “working-heart” apparatus were evaluated for cardiac func-
tion parameters and tissue biomarker correlates of physiological
regulation of heart activity. Potentially toxic effects of BC on car-
diomyocyte function were conducted by in vitro studies of BC
dosage effect on H9c2 cells. The comparison of outcomes in hearts
from animals treated with low-dose, high-dose BC and vehicle, pro-
vided a clear perspective into how this compound affected features
of heart function relevant to maintenance of healthy heart activity
and treatment of disease.
2. Materials and methods
2.1. Animals
The experiments were accomplished using adult male rats
(Charles River Laboratories), with a body weight range of
350–400 g. All animals received humane care in compliance with
the “Principles of Laboratory Animal Care” (formulated by the U.S.
National Society for Medical Research, as described in U.S. National
Institutes of Health publication No. 86-23, revised 1996) and the
“Guide for the Care and Use of Laboratory Animals”. Maintenance
and treatment of animals used in the present study was addition-
ally approved by the Institutional animal care and use committee of
the University of Debrecen, Debrecen, Hungary. The animals were
housed in wire-bottomed cages (three rats per cage) throughout
the study and were maintained on a 12:12-h light–dark cycle; and
provided with laboratory rodent chow pellets, and water ad libi-
tum.
2.2. Groups and administration of ˇ-carotene
Rats used in the present study were segregated into 3 groups
and gavage-administered the following agents: hydroxyethyl
cellulose-water (1:4) vehicle control (C); LD–BC (30 mg/kg/day)
and HD–BC (150 mg/kg/day) suspended in hydroxyethyl cellulose-
water, respectively. BC was  obtained from Sigma–Aldrich Kft.
(Budapest, Hungary).
2.3. Ischemia-reperfusion and isolated working hearts
Following 4-week treatment with vehicle or BC, the rats were
anesthetized with intraperitoneal injections of ketamine-xylazine
(75/10 mg/kg), with heparin anticoagulant administered intraperi-
toneally (1000 IU/kg). After thoracotomy, the hearts were excised
and placed in ice-cold modiﬁed Krebs-Henseleit bicarbonate buffer
(118.5 NaCl, 4.7 KCl, 2.5 CaCl2 × H2O, 25 NaHCO3, 1.2 KH2PO4, 1.2
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gSO4, and 10.0 glucose (in mM)), then cannulated through the
orta and perfused in a Langendorff apparatus in “non-working”
ode (100 cm of water) for 5 min  to ﬂush blood out from the hearts.
ubsequently, Langendorff perfusion was conducted using a cannu-
ated pulmonary vein, during which the isolated heart preparatum
as switched to working mode (at a ﬁlling pressure of 17 cm of
he buffer). After 10 min  of working perfusion, 30 min  of global
schemia (ISA) was initiated for each procedure, by clamping the
ulmonary inﬂow and the aortic outﬂow. At the end of the ischemic
eriod, 120 min  of reperfusion (REP) was initiated by unclamping
he inﬂow and outﬂow lines. The ﬁrst 10 min  of REP was  conducted
n Langendorff mode to avoid the fatal ventricular arrhythmias as
escribed [22].
.4. Cardiac function measurements
Baseline assessment of cardiac function for each isolated heart
as made following 10 min  of working perfusion. To examine the
ecovery of the left ventricle, these parameters were measured after
0, 60, and 120 min  of REP. Cardiac function evaluation for each
xperiment was conducted as previously described [22]. Brieﬂy,
eart rate (HR) was measured using a computer acquisition system
ADInstruments, PowerLab, Castle Hill, Australia); coronary ﬂow
CF) values were obtained by timed collection of efﬂuent draining
rom each heart; aortic ﬂow (AF) measurements were made using
 calibrated ﬂow meter; cardiac output (CO) was generated as the
um of AF and CF. Stroke volume (SV) was calculated as the quotient
f CO/HR [23]; and alteration in SV values, as a function of treat-
ents, were calculated as the ratio of SV at reperfusion divided by
aseline SV and multiplied by 100.
.5. Infarct size determination
Estimations of infarct size (IS) were conducted using the triph-
nyl tetrazolium chloride (TTC) staining method as previously
escribed [22]. Brieﬂy, following each 30-min ISA/120-min REP
eriod, hearts were perfused with 50 ml  1% (w/v) solution of TTC
n phosphate buffer (pH 7.4), and the samples were stored at
70 ◦C for subsequent analysis. The frozen samples were sectioned,
eighted, and blotted dry. The dried sections were scanned on
n Epson J232D ﬂat-bed scanner. The infarcted area (white col-
ration) and the risk area (entire scanned section) were measured
sing planimetry software (Image J, National Institute of Health,
ethesda, Maryland, USA). Estimates of infarcted zone magnitude
ere subsequently obtained by multiplying infarcted areas by
eight of each slice. The resulting numbers represent weight of
he risk zone and the infarcted zone. Infarct size was  expressed as
ercentage of the weight of infarcted tissue and the weight of risk
one (whole heart) [13].
.6. Western blot analysis of heart tissue
Content of HO-1 protein in the myocardium were obtained by
estern blot as previously described [22]. Brieﬂy, approximately
00 mg  of left ventricular myocardial tissue were homogenized on
ce using a tissue homogenizer (IKA T10 basic ULTRA-TURRAX®)
n isolating buffer (25 mM Tris–HCl, 25 mM NaCl, 1 mM ortho-
anadate, 10 mM NaF, 10 mM pyrophosphate, 10 mM okadaic acid,
.5 mM EDTA, 1 mM PMSF, and 1 × protease inhibitor cocktail)
nd centrifuged at 2000 rpm at 4 ◦C for 10 min. The supernatants
ere transferred to fresh tubes and centrifuged at 10,000 rpm at
◦C for 20 min, after which the resulting supernatant was used
s cytosolic fraction. The protein concentration was  measured by
D-1000 Nano drop spectrophotometer with BCA Protein Assay
it (Thermo Scientiﬁc, Rockford, IL). Thirty g of protein in each
ample were loaded in 10% polyacrylamide gel and resolved usingesearch 100 (2015) 148–156
SDS-PAGE electrophoresis and then transferred to 0.45 m pore
size nitrocellulose membrane to concentrate the samples. After
blocking the membranes with 7% nonfat dry milk in TBST, mem-
branes were incubated overnight with primary antibody solution
in 1% of nonfat dry milk in TBST (GAPDH 1/40000, antibody was
obtained from Cell Signaling Technology, Boston, MA; and HO-1
1/50 was  ordered from Sigma–Aldrich Kft. Budapest, Hungary) at
4 ◦C. Then, the membranes were washed 3 times, each for 10 min, in
TBST and incubated with horseradish peroxidase-conjugated sec-
ondary antibody solution (Cell Signaling Technology) containing
1% of nonfat dry milk in TBST, for 2 h at room temperature. The
membranes were treated with Western blot Enhanced Chemilu-
minescent HRP substrate (Millipore, Billerica, MA)  to visualize the
bands. After the Enhanced Chemiluminescent treatment, the mem-
branes were exposed on X-ray ﬁlms (Agfa, Mortsel, Belgium). The
ﬁlms were then digitalized by ﬂat-bed scanner (Epson J232D) and
analyzed using ImageJ program and normalized the HO-1 band
intensities to GAPDH.
2.7. MTT  cell viability assays for ˇ-carotene cytotoxicity
Evaluation of BC cytotoxicity on cellular survival was
accomplished using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay as previously described
[24]. Brieﬂy, H9c2 cells (ATCC, CRL-1446, LGC Standards GmbH,
Wesel Germany) dissociated by trituration in medium (Dulbecco’s
modiﬁed eagle’s medium from Sigma with 10% FBS, 1% penicillin-
streptomycin), were seeded into 96 well plates at a density of
3000 cells/well and cultured for 1 day to establish adhesion of the
wells. BC containing medium was prepared as described by Wertz
et al. for keratinocyte cultures with some modiﬁcations [25]. Cells
were treated with 0, 2.5, 5, 10 and 20 M BC for 4 h, respectively.
Next, following a 30-min incubation period, half of the wells
were treated with 125 M H2O2. Four hours later, addition of
20 l MTT  solution (5 mg/ml  in PBS) to each well and an addi-
tional 3 h incubation at 37 ◦C to allow mitochondrial uptake, the
medium was  removed and cells were lysed by addition of 150 l
of isopropanol, incubated for 15 min  followed by measurement
of absorbance at 570 and 690 nm using a plate reader (FLUOstar
OPTIMA, BMG  Labtech). Within each experiment, absorbance
values were averaged across 4 replicate wells and repeated 3
times. BC cytotoxic effect assessments were estimated based on
linear correlation of absorbance values with MTT-associated H9c2
viability and reported as percentage of cells surviving 4 h of BC
exposure relative to control cells not exposed to BC.
2.8. Tissue antioxidant capacity (TAC)
TAC of heart tissue was  measured using the CS0790-1KT antiox-
idant assay kit (Sigma–Aldrich Kft., BP., Hungary). Brieﬂy, at the
end of reperfusion, the hearts were frozen and stored at −70 ◦C
until analysis. Approximately, 100 mg  of left ventricular myocar-
dial tissue from each heart were homogenized in 0.5 ml of 1 × assay
buffer, centrifuged at 12,000 rpm, for 15 min  at 4 ◦C and the
supernatants collected for assay. Following sample preparation
according to manufacturer’s instructions, the absorbance was mea-
sured at 405 nm using a plate reader (FLUOstar OPTIMA, BMG
Labtech). TAC values for each heart were derived from absorbance
values and expressed as Trolox equivalent (M).
2.9. Statistical analysisStatistical analyses were performed using GraphPad Prism 5
software. The data are expressed as mean ± SEM. One-way ANOVA
followed by Bonferroni post-test was  carried out for heart func-
tion data analysis. MTT  data were compared by t-test. For Western
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ollowed by Tukey’s post-test was conducted. Differences were
onsidered signiﬁcant at values of P < 0.05.
. Results
.1. ˇ-Carotene dose effects on cardiac function in isolated hearts
ubjected to I/R
Fig. 1 shows the dose-responsive inﬂuence of 0, 30 or
50 mg/kg/day BC gavage-administered to rats during a 4-week
eriod on cardiac function in hearts isolated from the animals and
ubjected to 30 min  of global ISA and 120 min  of REP in a “working-
eart” apparatus. No BC-mediated effects on AF were observed
n hearts not subjected to REP, however, relative to hearts fromction in isolated working hearts.
vehicle-treated control animals, hearts from animals subjected to
30 min  of ISA followed by 30 and 60 min  of REP exhibited signiﬁ-
cantly increased AF when taken from rats treated with LD–BC; but
interestingly, not which were subjected to 120 min  of REP or from
those fed with HD-BC (Fig. 1A). No signiﬁcant BC dosage effects
on CF were observed in non-reperfused hearts, or in hearts from
animals subjected to 30 min  of I/R (Fig. 1B). Furthermore, HD–BC
treatment resulted in a signiﬁcant increase on CF values after 60
and 120 min  of REP relative to organs from non-BC-treated controls
(P < 0.05). Likewise CO in non-ISA/REP hearts and those subjected to
120 min  of REP did not vary signiﬁcantly as a result of BC treatment,
whereas signiﬁcant CO increases in these hearts relative to organs
from non-BC-treated controls were observed in those sustaining
reperfusion periods of 30 min  (P < 0.05) and 60 min  (P < 0.05) from
rats receiving 30 mg/kg/day BC, but not 150 mg/kg/day of the agent
152 E. Csepanyi et al. / Pharmacological Research 100 (2015) 148–156
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Fig. 1C). Treatment of animals with 150 mg/kg/day BC resulted in
igniﬁcant increase in HR for I/R hearts (P < 0.05) (Fig. 1D). Evalua-
ion of the effects of BC on heart SV, revealed no signiﬁcant BC effect
n this variable in non-I/R hearts, or organs subjected to I/R. It was
urther noted that SV values in hearts receiving 30 and 60 min  of
EP from animals treated with 150 mg/kg/day BC were reduced;
owever it was not signiﬁcant, relative to those from rats receiving
ow BC dose (Fig. 1E). This apparent loss of cardioprotection at ele-
ated BC dosage was further conﬁrmed by measurement of stroke
olume decline (dSV). These results demonstrated that relative to
on-I/R hearts, hearts subjected to 30 and 60, but not 120 min  of
EP exhibited lesser declines in stroke volume when taken from
nimals treated with 30 mg/kg/day BC than from rats receiving 0
r 150 mg/kg/day BC; however, it did not reach the signiﬁcant level.
Fig. 1F).
Hearts were isolated from 3 groups of rats (n = 6 per group).
ats in each test group received hydroxyethyl cellulose-water (1:4)
ehicle control (white bars); BC 30 mg/kg/day (black-shaded bars);
nd BC 150 mg/kg/day (gray-shaded bars) and sacriﬁced following
 4-week time period of BC treatment. Hearts isolated from each rat
ere subjected to 30 min  of global ISA followed by either 120 min  of
EP in an isolated “working-heart” apparatus to induce I/R-induced
njury and evaluated for selected cardiac functions. Results are
hown as average values from each group of animals ± SEM of AF
1A); CF (1B); CO (1C); HR (1D); SV (1E); and dSV (1F). *P < 0.05 for
omparison of the magnitude of each cardiac function measured in
ach test group receiving BC, relative to hearts from vehicle-treated
ontrol animals. #P < 0.05 for comparison of the magnitude of car-
iac function measured in LD–BC relative to hearts from HD–BC
reated animals.
.2. ˇ-Carotene dose effects on I/R-induced infarct zone extent
nd tissue antioxidant capacity
The inﬂuence of BC on the extent of I/R injury-associated infarct
ones is shown in Fig. 2A. Macroscopic analysis of TTC solution-
erfused heart sections from rats subjected to 30 min  of global
SA followed by 120 min  of REP in a “working-heart” apparatus
evealed that LD–BC treatment, correlated with signiﬁcant reduc-
ion of the extent of infarcted myocardium relative to the control
alues (*P < 0.05). This protective effect is abolished in hearts taken
rom animals treated with high-dose BC (#P < 0.05); moreover, the
verage extent of I/R-induced infarcted zones of hearts of these ani-itude (A) and tissue antioxidant capacity (B).
mals was  non-signiﬁcantly increased relative to hearts from rats
administered vehicle only.
The phenomenon of diminished BC-mediated protective effect
on cardiac physiology was also dramatically illustrated in outcomes
of experiments to assess contribution of the agent to tissue antiox-
idant capacity (TAC), a process that has evolved as a homeostatic
countermeasure to oxidative stress. As shown in Fig. 2B, isolated,
I/R-injured working hearts taken from rats administered LD–BC,
exhibited TAC values signiﬁcantly in excess of vehicle-treated con-
trols (*P < 0.05) and hearts isolated from HD–BC treated animals
(#P < 0.05). Nevertheless, TAC values measured in hearts from ani-
mals received HD–BC were not signiﬁcantly higher that hearts from
control rats received vehicle.
Infarct size was  measured in hearts (n = 4) following 120 min
of REP by perfusion with triphenyl tetrazolium (TTC) solution, fol-
lowed by macroscopic analysis of transverse sections of each heart.
Average sizes of infarct zone for hearts in each group ± SEM are
shown for each treatment group. TAC values for each tissue sam-
ple is expressed as Trolox equivalent (M)  ± SEM are shown for
each treatment group. *P < 0.05 for comparison relative to values for
hearts from vehicle-treated control (C) animals. #P < 0.05 for com-
parison relative to values for hearts from HD–BC treated animals.
3.3. ˇ-Carotene effects on heme oxygenase-1 (HO-1) protein
expression
Myocardial tissue levels of HO-1, which is a major mediator of
cardiac homeostasis, were determined by Western blot analysis.
As shown in Fig. 3, the presence of HO-1 protein was evaluated
in isolated working hearts taken from control rats administered
hydroxyethyl cellulose-water vehicle (C), over 4 weeks; a second
test group given LD–BC; and a third group, fed with HD–BC. Hearts
excised from these animals were either sham-treated (BL-baseline)
(Fig. 3. panel A), or I/R-injured (I/R) (Fig. 3. panel B) by 30 min  of
global ISA and 120 min  of REP. The results show that in control
hearts which were not subjected to I/R (C-BL) HO-1 expression was
not signiﬁcantly different from non-injured hearts removed from
rats receiving LD–BC (LD–BL), while high dose treatment (HD–BL)
resulted in signiﬁcantly increased HO-1 level (*P < 0.05) (Fig. 3A).
Furthermore, in hearts from non-treated animals and subjected
to I/R (C-I/R), we  detected mild but non-signiﬁcant increase of
HO-1 compared to non-ischemic baseline hearts (C-BL) (Fig. 3B)
E. Csepanyi et al. / Pharmacological Research 100 (2015) 148–156 153
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hile, production of HO-1 protein in I/R injured hearts from rats
ed with either low-dose (LD-I/R) or high-dose BC (HD-I/R), was
igniﬁcantly higher compared to non-treated non-injured (C-BL)
roup (*P < 0.05) (Fig. 3B). Moreover, HO-1 expression in hearts
emoved from vehicle treated animals and subjected to I/R (C-
/R) was not signiﬁcantly different from hearts excised from rats
eceiving LD–BC and subjected to I/R (LD-I/R); however, hearts
rom high-dose treated animals expressed signiﬁcantly elevated
evels of HO-1 protein relative to corresponding levels measured in
ehicle-treated controls (C-I/R) (#P < 0.05) (Fig. 3B).
Expression of HO-1 protein in rat myocardium was  measured
n homogenized cardiac tissue samples from vehicle or BC treated
earts, with or without I/R injury. Western blot analyses were
onducted on each tissue homogenate in triplicate and the sig-
al intensity of resulting bands corresponding to HO-1 protein
as measured using the Scion for Windows Densitometry Image
rogram. Tissue content of each protein is shown as a ratio of arbi-
rary units for HO-1 protein to GAPDH signal. Data are expressed as
ean ± SEM of 6 different blots. *P < 0.05 for comparison of average
evels of HO-1 in ventricular myocardium from BC-treated animals,
ersus non-ischemic control (C-BL) hearts. #P < 0.05 for comparison
f average levels of HO-1 in ventricular myocardium from BC-
reated animals subjected to I/R, versus I/R-injured control (C-I/R)
earts.
.4. MTT  assay-based evaluation of ˇ-carotene cytotoxicityTo determine if the signiﬁcant loss of cardioprotective capacity
f BC when administered at the levels deﬁned as “high-dose” in the
resent study, experiments were carried out to evaluate cytotox-
city of the agent in rat H9c2 cardiomyoblasts, an in vitro model,Fig. 4. In vitro (MTT) assays for -carotene cytotoxicity on H9c2 cells.
which along with the MTT  cell viability assay, has proven to be a
highly versatile tool for use in cardiovascular pharmacology [26].
As shown in Fig. 4, signiﬁcant increases in H9c2 cell viability was
observed in cultures of these cells grown 24 h in Dulbecco’s medium
supplemented with 2.5, 5 and 10 M BC, relative to cells grown with
no BC added (*P < 0.05). Furthermore, this protective effect was not
observed in cells treated with 20 M of BC.
Evaluation of BC cytotoxicity on cellular survival was  accom-
plished using the MTT  assay. H9c2 cells grown 24 h in Dulbecco’s
modiﬁed eagle’s medium and treated with 0, 2.5, 5, 10 and 20 M
BC, were followed by 4-h treatments with 125 M H2O2 and
5 mg/ml  MTT  reagent, lysis of cells and measurement of absorbance
was at 570- and 690 nm.  Absorbance values were averaged across
4 replicate wells, and repeated 3 times. Outcomes are shown as
average percentage of cell viability for each BC dosage level, rela-
tive to control cultures not BC-treated. *P < 0.05 for comparison of
average% viability versus non BC-treated cultures.
4. Discussion
Outcomes of the present study contribute to emerging insight
into how widely available plant materials may  be used to enhance
strategies for maintenance of cardiovascular health and develop
novel therapeutic approaches. Here, the capacity of -carotene is
evaluated for its ability to alter processes resulting in reduced tis-
sue oxygenation, leading to ischemic injury to the heart and with
strong relevance to the kidneys, brain and many other organs [27].
A major ﬁnding reported here, is that increasing BC dosage of may
not add to any cardiovascular beneﬁts. Moreover, the agent may
mediate—and indeed, may  exacerbate existing pathological mech-
anisms.
The efﬁciency and vigor with which a heart is able to main-
tain healthy circulation may  be quantitatively described by cardiac
functional measurements, in particular, AF, CF, CO, SV and dSV
[28] and the ability of agents that enhance antioxidant signaling to
improve these functions in isolated ischemic/reperfused rat hearts
has previously been demonstrated [29]. Accordingly, the signiﬁ-
cant LD–BC-mediated improvement in AF (Fig. 1A), CO (Fig. 1C),
were not unexpected. Nevertheless, the apparent abolition or mit-
igation of these protective effects against I/R injury in rats treated
with BC at the higher dose is intriguing.
The rat model was selected for the present investigation
based on the well-known features of this animal’s physiology its
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idespread use in cardiovascular research [30], and extensive use
f these animals in previous cardiac-related drug discovery and
asic scientiﬁc work by authors of this report [10,11,13,22,31,32].
he experiments described here, were nevertheless undertaken
n the context of known limitations on the translational value of
arotenoid research using rat data. A signiﬁcant consideration in
tudies such as the present one, is that although rats and mice read-
ly convert BC to vitamin A, bioavailability of carotenoids through
ut absorption is very low, requiring administration of supraphys-
ologic BC dosages—greatly in excess of levels from any natural
ource [33]. The experiments were designed to partly offset this
imitation by administration of BC in a high dose range for all con-
itions. Accordingly, use of these outcomes and ﬁndings in design
f improved human healthcare strategies must be made conserva-
ively, taking into account experimental versus normal dietary or
herapeutic dose ranges. In the present study, even the lowest dose
f BC administered to rats is very high, equivalent to more than
 g/day/70 kg man. On a daily basis, a normal human diet may con-
ain 3 orders of magnitude less BC [34]. The degree of translational
alue that these ﬁndings have for managing cardiovascular dis-
ase, will require human nutritional studies—for which the present
tudy provides a guide to major outcomes that might be evalu-
ted. Here it is important to emphasize the value of human, versus
xtended animal studies. No single animal model completely repli-
ates BC absorption and metabolism of humans [33]. Moreover,
ince the present study was designed to obtain mostly qualitative
valuations of low-, versus high-dose BC effects on major cardiac
arameters, no attempt was made to determine precise rat-to-
uman dose equivalents. Thus, human clinical evaluations of the
ffects described here, constitute appropriate and easily accom-
lished follow-on studies.
Although data presented here do not allow a comprehen-
ive mechanistic analysis, the observation that low-dose-mediated
mprovement of AF and CO observed at 30 and 60, but not
20 min  of post-ischemic REP suggest that BC at the lower dosage
s effectively quenching oxidative stress-promoting prooxidant
ompounds produced by cardiac tissue as a consequence of
nﬂammatory reactions triggered by I/R-induced damage and/or
therwise counteracting adverse effect of these metabolites. If this
s the case, then it is reasonable to predict that the higher levels
f oxidative stress present with longer reperfusion periods, might
verwhelm the quenching ability of BC, signiﬁcantly diminishing
he beneﬁcial effects of the 150 mg/kg/day treatments. The rela-
ive ability of BC to quench prooxidant molecules may also account
or differences in magnitudes of myocardial infarct zones and tissue
ntioxidant capacity shown in Fig. 2. The signiﬁcantly reduced aver-
ge infarct size observed in I/R-injured hearts of animals treated
ith LD–BC, relative those not administered the agent, is consistent
ith previous work by authors of the present report, demonstrating
hat the extent of myocardial infarct zones in I/R-injured hearts may
e diminished with agents that reduce oxidative stress [13,22,35].
ccordingly, the signiﬁcant LD-BC-mediated reduction of infarct
ize (Fig. 2A) and increased TAC (Fig. 2B), were not surprising.
oreover, abolition of these effects in hearts of animals treated
ith 150 mg/kg/day BC, would be expected if the quenching abil-
ty of the molecule were suppressed at a higher dose, allowing a
ore prooxidant cardiac tissue environment at the higher dosage.
he dose-responsively increased expression of HO-1 by myocardial
issue observed for both BC and duration of REP shown in Fig. 3, fur-
her supports the possibility that BC loses quenching potential and
ay  become prooxidant as dosage increases. HO-1 is an ubiqutous
ntioxidant response to a wide variety of oxidative stressors, hence
t is expected that its expression would increase as a result of I/R
njury [27].
It is further expected that BC acting as a protective antioxi-
ant would not be diminished by BC also acting as a quenchingesearch 100 (2015) 148–156
agent and contributor to TAC, as shown in Fig. 2B. However, if
this model is accurate, BC at the elevated dose, acting to promote
prooxidant tissue environments is expected to stimulate HO-1
production—which is what was observed (Fig. 3). The possibility
of such a mechanism is additionally validated, by the observa-
tion that HO-1 expression in I/R-injured hearts of rats treated
with high-dose BC (HD-I/R) was elevated relative to production
of the enzyme by hearts from rats treated with high dose BC,
but not subjected to I/R injury (HD-BL) (Fig. 3), since elevated
HO-1 expression would be an expected consequence of signif-
icantly higher levels of oxidative stress present in I/R-injured
tissue.
This analysis is supported, albeit to a minor extent by out-
comes of the in vitro assays for BC cytotoxicity on H9c2 rat
myocardial cells. Outcomes of these experiments (Fig. 4) show
that viability of these cells is signiﬁcantly enhanced in compari-
son to unstimulated control cultures, by addition of BC at 2.5, 5
and 10 M,  with a loss of this effect at 20 M. Although these
data are insufﬁcient on which to base deﬁnitive conclusions, the
results suggest that as BC dosage is increased, the protective effect
of the compound is diminished and may  include deleterious prop-
erties.
An explanation for apparent cardioprotective effect of BC at one
selected dosage and mitigation or elimination of that protection
at a higher dose is speculative based on the outcomes presented
here. This notwithstanding, previous studies provide some clues
as to the mechanisms that may  underlie the observations in this
report. It is known that free radical species of the kind responsible
for oxidative stress in vertebrate tissues, react with BC to produce
prooxidant degradation products, such as apo-8′-beta-carotenal,
that are particularly damaging to subcellular organelles, partic-
ularly mitochondria, resulting in further disruption of the redox
balance of myocardial cells, oxidation of critical proteins and exac-
erbation of damage caused by ischemia-reperfusion injury [15,16].
Ironically, the HO-1 expression response to oxidative stressors
may  also contribute to loss of cardioprotection at elevated BC
dosage. This is a possibility because heme oxygenases, including
HO-1, reduce oxidative stress by degrading heme produced in the
tissue by red blood cell turnover to produce metabolites with cyto-
protective qualities, principally biliverdin (converted rapidly into
bilirubin) and subtoxic levels of carbon monoxide, which is pro-
motes antioxidant signaling. Interestingly, although ferrous iron
(Fe2+) also produced by normal HO-1 activity is a benign metabo-
lite and readily cleared, its presence under some physical settings
determines whether BC acts as an antioxidant or prooxidant com-
pound [36]. This property has potential consequences that are
paradoxical in the context of the putative role of HO-1. Normally,
increased activity of this enzyme reduces oxidative stress and pro-
tects tissues from toxic insult. In the present study, I/R injury to
cardiac tissue, strongly activated HO-1, resulting in elevated lev-
els of its metabolic products, including Fe2+. Since, as described
by Andersen et al., Fe2+ enhances the prooxidant properties of
BC, inﬂuences that elevate HO-1 in the presence of high BC lev-
els, potentially overwhelm the cytoprotective effects of HO-1 and
increase oxidative stress on a tissue. This conclusion is speculative
and will require further analysis of BC cardiovascular effects. Such
a mechanism is nevertheless consistent with the known behav-
ior of BC in the presence of Fe2+ – and if valid, accounts for the
results shown in Fig. 4. Potential relevance of this ﬁnding to man-
agement of cardiovascular disease is provided by an observation
that an inducer of HO-1 administered orally to human patients
signiﬁcantly altered serum levels of transferrin, which is the phys-
iologic transport molecule for Fe2+ [37] indicating that aspects of
iron metabolism that may  also impact BC utilization may be mod-
ulated by drugs that affect HO-1 activity and possibly selective
chelators of Fe2+.
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. Conclusions
The ﬁndings described above, suggest that the level of HO-1
ctivity in response to I/R injury may  be a critical determinant for
he role of BC as either a protective agent against I/R-induced heart
amage, or as a contributor to I/R-related syndromes through acti-
ation of its prooxidant properties. Validity of this model depends
n the degree to which redox activities of BC may  be inﬂuenced
n either direction by presence of Fe2+—which has been identiﬁed
s a primary factor. Ongoing characterization of these processes
s continuing by this laboratory. A particularly valuable outcome
nticipated for this ongoing research initiative, is the potential for
ombining use of BC with HO-1 inducers, such as the sour cherry
eed extracts described by Csiki et al. [37], in modulation of the
linical effects of BC.
. Future directions
Current efforts by authors of this report to mitigate the car-
iotoxic effects of -carotene, while retaining the cardioprotective
alue of this compound and also HO-1 activity, are focused on
evelopment of a novel functional food class containing whole leaf
xtract of Tamarindus indica L. (tamarind), which in March 2015
as reported to chelate ferrous iron, with a binding constant of
.085 mol  l−1 [38]. It is predicted that Fe2+ chelation in this potency
ange will augment transferrin activity to the extent that the capac-
ty of endogenous HO-1 to reduce oxidative stress will be retained,
hile simultaneously counteracting BC toxicity by removal of Fe2+.
his conclusion is currently speculative and await outcome of ongo-
ng studies.
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